ImmunityBio (IBRX): frequently asked questions
Short answers, each linking to the part of the full report that argues it. The 2032 sum-of-the-parts runs $3.07 bear, $21.30 base and $46.39 bull from a $7.32 publication price; this report sets no target, and every figure here is drawn from that document, which cites 191 primary sources.
The author holds a substantial long position in ImmunityBio and is not disinterested. This is analysis rather than investment advice. The bear case is $3.07, roughly 58% below the publication price, and it is a branch of the model rather than a stress test.
What is the bull case for IBRX?
$46.39 a share by 2032. It assumes the BCG-naive indication arrives and takes a large share of a pool four times the current one, revenue reaches roughly $4.6bn, and the market pays 11x for it. It also assumes the pipeline delivers: systemic ANKTIVA in lung cancer, and enough of the immune reconstitution thesis to carry a $1.4bn line. Each of those is a separate bet, and the bull case requires most of them to land.
Section 16 · ValuationWhat is the bear case for IBRX?
$3.07 a share by 2032. It assumes the BCG-naive indication does not arrive, revenue reaches roughly $1.05bn, the multiple compresses to 4x, and the share count climbs to 1.65bn as the company funds itself through the trough. That is a loss of well over half the publication price, and it is a real branch of the model rather than a stress test.
Section 16 · ValuationHow much revenue does ANKTIVA generate?
$50.7m in the second quarter of 2026, the eighth consecutive quarter of sequential growth, at roughly 99% gross margin. The margin is that high because the drug substance was manufactured years ago and already written off, so it will fall as new material is made.
Section 02 · The commercial baseWhen will ImmunityBio be profitable?
The base case reaches cash-flow breakeven in the first quarter of 2028, with cash troughing near $113m before that. That depends on the BCG-naive indication arriving on schedule. In the bear case it does not arrive and breakeven does not happen inside the forecast window.
Section 06 · Revenue buildWhat happens on January 6, 2027?
The FDA decides on ANKTIVA for BCG-unresponsive papillary-only disease. The same application was refused filing in May 2025, and the agency then asked for a randomized trial against chemotherapy that was never started. It was resubmitted on extrapolation instead, and the acceptance letter reserved that question rather than settling it. No agent has ever held a label for this population.
Section 15 · Catalysts and timingWill ImmunityBio need to raise more money?
A $480m related-party convertible note matures on December 31, 2027. Above $5.427 it converts to equity and no cash leaves the business. Below that the company cannot repay from the trough and something has to be negotiated with a holder who is also the controlling shareholder. The outcome turns on the share price rather than the cash balance.
Section 16 · ValuationWho are ANKTIVA's competitors?
INLEXZO from Johnson & Johnson, ADSTILADRIN from Ferring, KEYTRUDA from Merck and cretostimogene from CG Oncology in the same second-line setting. ANKTIVA is the only one that requires BCG, which is a structural disadvantage while supply is short. Response rates are not comparable across these trials, and the report explains why the highest number does not win.
Section 03 · Competitive landscapeWhy did the FDA send ImmunityBio a warning letter?
In March 2026 the FDA found that a television advertisement and a podcast appearance by the founder made false or misleading claims about ANKTIVA, including that it could treat all cancers. Two earlier untitled letters had addressed the same conduct. The shares fell 21% on publication and a securities class action followed.
Section 14 · Ownership and governanceDoes ANKTIVA work outside the bladder?
Instilled into the bladder it works locally and produces no measurable systemic exposure, so a bladder patient is not receiving a body-wide immune benefit. Given under the skin it is approved in Saudi Arabia and the UAE and has no US approval. A randomized Phase 3 in lung cancer reads out around 2028, and that trial is where the systemic thesis is settled.
Section 08 · The mechanismWhat is the immune reconstitution opportunity worth?
On the narrow reading, $2.0 to 4.5bn a year in the United States at a hundred thousand dollars a course. On the broad reading, roughly $25bn. The difference turns on whether a label would cover a deficit that resolves on its own, and no regulator has approved any therapy for acquired lymphocyte deficiency. The model carries this line at a fraction of either figure.
Section 09 · Immune reconstitutionWhat would prove this analysis wrong?
A negative QUILT-2.005 readout would remove the largest modelled line. A positive SunRISe-3 would devalue the naive thesis regardless of ANKTIVA's own data. A complete response letter in January would close the papillary route. Every section that models something states its own falsifier, which is the test this report asks to be held to.
Section 18 · ConclusionThese answers compress a 104-page document. The reasoning, the sources and the
parts that cut against the thesis are in the full report, and the model is
published as a spreadsheet you can change.
© 2026 Edwin P. Jacques. Quote, excerpt and link with attribution.